Cargando…
Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study
Cancer patients are at risk of suffering from cardiovascular diseases (CVD). Nevertheless, the impact of cardiovascular comorbidity on all-cause mortality (ACM) in large clinical cohorts is not well investigated. In this retrospective cohort study, we collected data from 40,329 patients who were sub...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898338/ https://www.ncbi.nlm.nih.gov/pubmed/35312818 http://dx.doi.org/10.1007/s00392-022-02001-6 |
_version_ | 1784882405654396928 |
---|---|
author | Finke, Daniel Heckmann, Markus B. Wilhelm, Susanna Entenmann, Lukas Hund, Hauke Bougatf, Nina Katus, Hugo A. Frey, Norbert Lehmann, Lorenz H. |
author_facet | Finke, Daniel Heckmann, Markus B. Wilhelm, Susanna Entenmann, Lukas Hund, Hauke Bougatf, Nina Katus, Hugo A. Frey, Norbert Lehmann, Lorenz H. |
author_sort | Finke, Daniel |
collection | PubMed |
description | Cancer patients are at risk of suffering from cardiovascular diseases (CVD). Nevertheless, the impact of cardiovascular comorbidity on all-cause mortality (ACM) in large clinical cohorts is not well investigated. In this retrospective cohort study, we collected data from 40,329 patients who were subjected to cardiac catherization from 01/2006 to 12/2017 at University Hospital Heidelberg. The study population included 3666 patients with a diagnosis of cancer prior to catherization and 3666 propensity-score matched non-cancer patients according to age, gender, diabetes and hypertension. 5-year ACM in cancer patients was higher with a reduced left ventricular function (LVEF < 50%; 68.0% vs 50.9%) or cardiac biomarker elevation (high-sensitivity cardiac troponin T (hs-cTnT; 64.6% vs 44.6%) and N-terminal brain natriuretic peptide (NT-proBNP; 62.9% vs 41.4%) compared to cancer patients without cardiac risk. Compared to non-cancer patients, NT-proBNP was found to be significantly higher (median NT-proBNP cancer: 881 ng/L, IQR [254; 3983 ng/L] vs non-cancer: 668 ng/L, IQR [179; 2704 ng/L]; p < 0.001, Wilcoxon-rank sum test) and turned out to predict ACM more accurately than hs-cTnT (NT-proBNP: AUC: 0.74; hs-cTnT: AUC: 0.63; p < 0.001, DeLong’s test) in cancer patients. Risk factors for atherosclerosis, such as diabetes and age (> 65 years) were significant predictors for increased ACM in cancer patients in a multivariate analysis (OR diabetes: 1.96 (1.39–2.75); p < 0.001; OR age > 65 years: 2.95 (1.68–5.4); p < 0.001, logistic regression). Our data support the notion, that overall outcome in cancer patients who underwent cardiac catherization depends on cardiovascular comorbidities. Therefore, particularly cancer patients may benefit from standardized cardiac care. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-022-02001-6. |
format | Online Article Text |
id | pubmed-9898338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-98983382023-02-05 Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study Finke, Daniel Heckmann, Markus B. Wilhelm, Susanna Entenmann, Lukas Hund, Hauke Bougatf, Nina Katus, Hugo A. Frey, Norbert Lehmann, Lorenz H. Clin Res Cardiol Original Paper Cancer patients are at risk of suffering from cardiovascular diseases (CVD). Nevertheless, the impact of cardiovascular comorbidity on all-cause mortality (ACM) in large clinical cohorts is not well investigated. In this retrospective cohort study, we collected data from 40,329 patients who were subjected to cardiac catherization from 01/2006 to 12/2017 at University Hospital Heidelberg. The study population included 3666 patients with a diagnosis of cancer prior to catherization and 3666 propensity-score matched non-cancer patients according to age, gender, diabetes and hypertension. 5-year ACM in cancer patients was higher with a reduced left ventricular function (LVEF < 50%; 68.0% vs 50.9%) or cardiac biomarker elevation (high-sensitivity cardiac troponin T (hs-cTnT; 64.6% vs 44.6%) and N-terminal brain natriuretic peptide (NT-proBNP; 62.9% vs 41.4%) compared to cancer patients without cardiac risk. Compared to non-cancer patients, NT-proBNP was found to be significantly higher (median NT-proBNP cancer: 881 ng/L, IQR [254; 3983 ng/L] vs non-cancer: 668 ng/L, IQR [179; 2704 ng/L]; p < 0.001, Wilcoxon-rank sum test) and turned out to predict ACM more accurately than hs-cTnT (NT-proBNP: AUC: 0.74; hs-cTnT: AUC: 0.63; p < 0.001, DeLong’s test) in cancer patients. Risk factors for atherosclerosis, such as diabetes and age (> 65 years) were significant predictors for increased ACM in cancer patients in a multivariate analysis (OR diabetes: 1.96 (1.39–2.75); p < 0.001; OR age > 65 years: 2.95 (1.68–5.4); p < 0.001, logistic regression). Our data support the notion, that overall outcome in cancer patients who underwent cardiac catherization depends on cardiovascular comorbidities. Therefore, particularly cancer patients may benefit from standardized cardiac care. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-022-02001-6. Springer Berlin Heidelberg 2022-03-21 2023 /pmc/articles/PMC9898338/ /pubmed/35312818 http://dx.doi.org/10.1007/s00392-022-02001-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Finke, Daniel Heckmann, Markus B. Wilhelm, Susanna Entenmann, Lukas Hund, Hauke Bougatf, Nina Katus, Hugo A. Frey, Norbert Lehmann, Lorenz H. Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study |
title | Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study |
title_full | Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study |
title_fullStr | Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study |
title_full_unstemmed | Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study |
title_short | Coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study |
title_sort | coronary artery disease, left ventricular function and cardiac biomarkers determine all-cause mortality in cancer patients—a large monocenter cohort study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898338/ https://www.ncbi.nlm.nih.gov/pubmed/35312818 http://dx.doi.org/10.1007/s00392-022-02001-6 |
work_keys_str_mv | AT finkedaniel coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy AT heckmannmarkusb coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy AT wilhelmsusanna coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy AT entenmannlukas coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy AT hundhauke coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy AT bougatfnina coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy AT katushugoa coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy AT freynorbert coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy AT lehmannlorenzh coronaryarterydiseaseleftventricularfunctionandcardiacbiomarkersdetermineallcausemortalityincancerpatientsalargemonocentercohortstudy |